OncoMatch/Clinical Trials/NCT06371534
A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults
Is NCT06371534 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including QL2109 and DARZALEX FASPRO® for tumor.
Treatment: QL2109 · DARZALEX FASPRO® — The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL2109 with DARZALEX FASPRO® in healthy male volunteers. Participants will receive a single injection of QL2109/ DARZALEX FASPRO® Researchers will compare pharmacokinetic, safety, and immunogenic similarities between the two groups.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: monoclonal antibody
Use of monoclonal antibody, cell therapy, etc. within 6 months before administration
Cannot have received: cell therapy
Use of monoclonal antibody, cell therapy, etc. within 6 months before administration
Cannot have received: (daratumumab)
daratumumab or its analogues or drugs targeting CD38 before administration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify